Whilst there is no guarantee of any sales revenue from the new Sinopharm agreement, it is nonetheless a great addition to JAT's portfolio of contracts as GF/JAT have secured exclusivity for the various brands it will supply to Sinopharm.
Based on this, I expect that GF might now be approached by suppliers or manufacturers of other products that want to penetrate the Chinese market.
Be interesting to see what happens here. Patience will be key to winning IMO.
JAT Price at posting:
5.4¢ Sentiment: Buy Disclosure: Held
